Market Overview

FDA Issues Review of Hemispherx's Ampligen Lacks Required Carcinogencity Tests

Related HEB
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
Hemispherx Joins The Ebola Game

View document.

Posted-In: News FDA

 

Related Articles (HEB)

Around the Web, We're Loving...

Get Benzinga's Newsletters